Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00738764 · ClinicalTrials.gov registry record · Phase 1

A Trial of PDL192 in Subjects With Advanced Solid Tumors

A Phase 1 study of Cancer, sponsored by Abbott.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT00738764: Completed Phase 1 study of Cancer, sponsored by Abbott.

NCT00738764 is a Phase 1 study of Cancer that has completed, run by Abbott. The registered enrollment target is 30 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00738764, a Phase 1 study of Cancer, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.

Conditions Studied

Interventions

  • BIOLOGICAL PDL192

Study Locations (2)

Arizona

  • Site Reference ID/Investigator# 53365 - Scottsdale

Colorado

  • Site Reference ID/Investigator# 53364 - Aurora

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-07
Est. Completion 2011-10
Phase Phase 1
Abbott

181 total trials

What the finished NCT00738764 record still lists

NCT00738764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which PDL192 is the first listed.

NCT00738764 reports a single indexed study location in Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT00738764 about?

NCT00738764 is a clinical study titled "A Trial of PDL192 in Subjects With Advanced Solid Tumors". This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.

What is the current status of trial NCT00738764?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-07. Estimated completion is 2011-10.

What conditions does trial NCT00738764 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT00738764?

The interventions under investigation include: PDL192 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00738764?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00738764 being conducted?

This trial has 2 study locations across Arizona, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00738764's enrollment target sits among peer trials

30 502nd of 615 higher than 93 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00738764, the US trial registry maintained by the National Library of Medicine. NCT00738764 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.